2024
Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial
Grilo C, Ivezaj V, Yurkow S, Tek C, Wiedemann A, Gueorguieva R. Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2024, 54: 3334-3344. PMID: 39258475, PMCID: PMC11496227, DOI: 10.1017/s003329172400148x.Peer-Reviewed Original ResearchEating-disorder psychopathologyBinge-eating disorderMaintenance treatmentAcute treatmentBinge-eating remission ratesCognitive-behavioral therapyEfficacy of lisdexamfetamineSignificant weight gainDouble-blind placebo-controlled trialAcute respondersLisdexamfetamine treatmentPsychopathological outcomesPosttreatment assessmentLisdexamfetaminePlacebo-controlled trialRandomized double-blind placebo-controlled trialSingle-site trialAssociated with significant weight lossPsychopathologyBinge-eatingRemission rateWeight lossPlaceboRelapse rateControl research
2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reductionNaltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial
Grilo C, Lydecker J, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2023, 53: 7775-7784. PMID: 37366017, PMCID: PMC10751383, DOI: 10.1017/s0033291723001800.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderBinge-eating remissionAcute treatmentMaintenance treatmentBinge-eating frequencyDouble-blind placebo-controlled trialBehavioral weight loss therapyWeight lossCo-occurring obesitySuccessful acute treatmentPlacebo-controlled trialWeight loss therapySignificant additional weight lossSingle-site trialAdditional weight lossAcute efficacyRemission rateAdult patientsComorbid obesityBupropionInitial interventionPosttreatment assessmentRespondersPlacebo
2016
Randomized controlled trial testing behavioral weight loss versus multi-modal stepped-care treatment for binge eating disorder
Grilo C. Randomized controlled trial testing behavioral weight loss versus multi-modal stepped-care treatment for binge eating disorder. European Psychiatry 2016, 33: s163. DOI: 10.1016/j.eurpsy.2016.01.321.Peer-Reviewed Original ResearchStepped-care treatmentAnti-obesity medicationsRemission rateWeight lossBehavioral weight lossCo-morbid obesityStepped-care modelObese BED patientsSignificant time effectInitial respondersTreatment challengesBED patientsMedicationsMixed model analysisPatientsBingePlaceboMonthsObesityBWLTreatmentStructured interviewsCBTDisordersMixed models
2005
Cognitive Behavioral Therapy Guided Self-Help and Orlistat for the Treatment of Binge Eating Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
Grilo CM, Masheb RM, Salant SL. Cognitive Behavioral Therapy Guided Self-Help and Orlistat for the Treatment of Binge Eating Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Biological Psychiatry 2005, 57: 1193-1201. PMID: 15866560, DOI: 10.1016/j.biopsych.2005.03.001.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyWeight lossSelf-help cognitive behavioral therapyAddition of placeboFacilitate weight lossTreat remission ratesPercent of patientsDouble-blind fashionPlacebo-controlled studyAddition of orlistatGreater weight lossGuided Self-HelpObese BED patientsBinge Eating DisorderRemission rateTreatment discontinuationClinical improvementObesity medicationsBED patientsCBTgshOrlistatPlaceboBehavioral therapyDisorder psychopathologyComparable improvementEfficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: A randomized double-blind placebo-controlled comparison
Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: A randomized double-blind placebo-controlled comparison. Biological Psychiatry 2005, 57: 301-309. PMID: 15691532, DOI: 10.1016/j.biopsych.2004.11.002.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyBehavioral therapyEfficacy of CBTTreatment of bingeTreat remission ratesCBT conditionCognitive featuresPsychological featuresPsychological distressDimensional measuresBingeRemission rateDouble-blind placebo-controlled comparisonDouble-blind fashionPlacebo-controlled comparisonPlacebo-controlled studyConsistent findingCompletersIndividual treatmentCertain medicationsPharmacological therapyITT analysisFluoxetineDisordersPlacebo